Advertisement

A Phase II Study of Telisotuzumab Vedotin in Patients With c–MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753)

Published:October 14, 2020DOI:https://doi.org/10.1016/j.cllc.2020.09.013

      Abstract

      Introduction

      Lung-MAP S1400K was designed to evaluate the response to telisotuzumab vedotin, an antibody-drug conjugate targeting c-MET, in patients with c-MET–positive squamous cell carcinoma (SCC).

      Patients and Methods

      Patients with previously treated SCC with c-MET–positive tumors (H score ≥ 150, Ventana SP44 assay) were enrolled into 2 cohorts: Cohort 1 (immune checkpoint inhibitor-naive) and Cohort 2 (immune checkpoint inhibitor refractory). Telisotuzumab vedotin 2.7 mg/kg was administered intravenously every 3 weeks until disease progression or unacceptable toxicity. Response assessments were performed every 6 weeks. The primary endpoint was response by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Secondary endpoints included progression-free survival, overall survival, response within cohort, duration of response, and toxicities. Interim analysis was planned after 20 evaluable patients, with ≥ 3 responses needed to continue enrollment.

      Results

      Forty-nine patients (14% of screened patients) were assigned to S1400K, 28 patients enrolled (15 in Cohort 1 and 13 in Cohort 2), and 23 were eligible. S1400K closed on December 21, 2018 owing to lack of efficacy. Two responses (response rate of 9%; 95% confidence interval, 0%-20%) were reported in cohort 1 (1 complete and 1 unconfirmed partial response), whereas 10 patients had stable disease, with a disease control rate of 52%. The median overall and progression-free survival was 5.6 and 2.4 months, respectively. There were 3 grade 5 events (2 pneumonitis, in Cohort 2, and 1 bronchopulmonary hemorrhage, in Cohort 1).

      Conclusion

      Telisotuzumab vedotin failed to meet the pre-specified response needed to justify continuing enrollment to S1400K. Pneumonitis was an unanticipated toxicity observed in patients with SCC.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Lung Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Herbst R.S.
        • Gandara D.R.
        • Hirsch F.R.
        • et al.
        Lung Master Protocol (Lung-MAP)-a biomarker-driven protocol for accelerating development of therapies for squamous cell lung cancer: SWOG S1400.
        Clin Cancer Res. 2015; 21: 1514-1524
        • Malik S.M.
        • Pazdur R.
        • Abrams J.S.
        • et al.
        Consensus report of a joint NCI thoracic malignancies steering committee: FDA workshop on strategies for integrating biomarkers into clinical development of new therapies for lung cancer leading to the inception of “master protocols” in lung cancer.
        J Thorac Oncol. 2014; 9: 1443-1448
        • Ma P.C.
        • Maulik G.
        • Christensen J.
        • Salgia R.
        c-Met: structure, functions and potential for therapeutic inhibition.
        Cancer Metastasis Rev. 2003; 22: 309-325
        • Park M.
        • Dean M.
        • Kaul K.
        • Braun M.J.
        • Gonda M.A.
        • Vande Woude G.
        Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors.
        Proc Natl Acad Sci U S A. 1987; 84: 6379-6383
        • Sadiq A.A.
        • Salgia R.
        MET as a possible target for non-small-cell lung cancer.
        J Clin Oncol. 2013; 31: 1089-1096
        • Birchmeier C.
        • Gherardi E.
        Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase.
        Trends Cell Biol. 1998; 8: 404-410
        • Gherardi E.
        • Birchmeier W.
        • Birchmeier C.
        • Vande Woude G.
        Targeting MET in cancer: rationale and progress.
        Nat Rev Cancer. 2012; 12: 89-103
        • Waqar S.N.
        • Morgensztern D.
        • Sehn J.
        MET mutation associated with responsiveness to crizotinib.
        J Thorac Oncol. 2015; 10: e29-e31
        • Edelman M.
        • Spigel D.
        • O’Byrne K.
        • et al.
        The prevalence of MET expression by immunohistochemistry (IHC) in the MetLung (OAM4971g) trial: a randomized, placebo-controlled, phase III study with erlotinib + onartuzumab (MetMab) vs erlotinib + placebo in patients with previously treated non-small cell lung cancer.
        J Thorac Oncol. 2013; 8 (Abstract MO1312.1307): S2-S1348
        • Dziadziuszko R.
        • Wynes M.W.
        • Singh S.
        • et al.
        Correlation between MET gene copy number by silver in situ hybridization and protein expression by immunohistochemistry in non-small cell lung cancer.
        J Thorac Oncol. 2012; 7: 340-347
        • Gao J.
        • Aksoy B.A.
        • Dogrusoz U.
        • et al.
        Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.
        Sci Signal. 2013; 6: pl1
        • Schildhaus H.U.
        • Schultheis A.M.
        • Ruschoff J.
        • et al.
        MET amplification status in therapy-naive adeno- and squamous cell carcinomas of the lung.
        Clin Cancer Res. 2015; 21: 907-915
        • Mok T.S.
        • Geater S.L.
        • Su W.C.
        • et al.
        A randomized phase 2 study comparing the combination of ficlatuzumab and gefitinib with gefitinib alone in Asian patients with advanced stage pulmonary adenocarcinoma.
        J Thorac Oncol. 2016; 11: 1736-1744
        • Spigel D.R.
        • Ervin T.J.
        • Ramlau R.A.
        • et al.
        Randomized phase II trial of onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.
        J Clin Oncol. 2013; 31: 4105-4114
        • Scagliotti G.
        • von Pawel J.
        • Novello S.
        • et al.
        Phase III multinational, randomized, double-blind, placebo-controlled study of tivantinib (ARQ 197) plus erlotinib versus erlotinib alone in previously treated patients with locally advanced or metastatic nonsquamous non-small-cell lung cancer.
        J Clin Oncol. 2015; 33: 2667-2674
        • Wang J.
        • Anderson M.G.
        • Oleksijew A.
        • et al.
        ABBV-399, a c-Met antibody drug conjugate that targets both MET amplified and c-Met overexpressing tumors, irrespective of MET pathway dependence.
        Clin Cancer Res. 2016; 23: 992-1000
        • Strickler J.H.
        • LoRusso P.
        • Yen C.-J.
        • et al.
        Phase 1, open-label, dose-escalation, and expansion study of ABT-700, an anti-C-met antibody, in patients (pts) with advanced solid tumors.
        J Clin Oncol. 2014; 32: 2507
        • Kang Y.-K.
        • LoRusso P.
        • Salgia R.
        • et al.
        Phase I study of ABT-700, an anti-c-Met antibody, in patients (pts) with advanced gastric or esophageal cancer (GEC).
        J Clin Oncol. 2015; 33: 167
        • Strickler J.H.
        • Weekes C.D.
        • Nemunaitis J.
        • et al.
        First-in-human phase I, dose-escalation and -expansion study of telisotuzumab vedotin, an antibody-drug conjugate targeting c-Met, in patients with advanced solid tumors.
        J Clin Oncol. 2018; 36: 3298-3306
        • Eisenhauer E.A.
        • Therasse P.
        • Bogaerts J.
        • et al.
        New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
        Eur J Cancer. 2009; 45: 228-247
        • Watermann I.
        • Schmitt B.
        • Stellmacher F.
        • et al.
        Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation?.
        Diagn Pathol. 2015; 10: 130
        • Hirsch F.R.
        • Bunn Jr., P.A.
        • Herbst R.S.
        “Companion diagnostics:” has their time come and gone?.
        Clin Cancer Res. 2014; 20: 4422-4424
        • Organ S.L.
        • Tsao M.S.
        An overview of the c-MET signaling pathway.
        Ther Adv Med Oncol. 2011; 3: S7-S19
        • Sabet Y.
        • Ramirez S.
        • Rosell Cespedes E.
        • et al.
        Severe acute pulmonary toxicity associated with brentuximab in a patient with refractory Hodgkin’s lymphoma.
        Case Rep Pulmonol. 2016; 2016: 2359437
        • Egloff H.
        • Kidwell K.M.
        • Schott A.
        Ado-trastuzumab emtansine-induced pulmonary toxicity: a single-institution retrospective review.
        Case Rep Oncol. 2018; 11: 527-533
        • Boyle T.A.
        • Khalil F.K.
        • Mino-Kenudson M.
        • et al.
        • Lung Cancer Mutation Consortium (LCMC) Pathologist Panel Group
        Round robin evaluation of MET protein expression in lung adenocarcinomas improves interobserver concordance.
        Appl Immunohistochem Mol Morphol. 2019;
        • Guo R.
        • Berry L.D.
        • Aisner D.L.
        • et al.
        MET IHC is a poor screen for MET amplification or MET exon 14 mutations in lung adenocarcinomas: data from a tri-institutional cohort of the Lung Cancer Mutation Consortium.
        J Thorac Oncol. 2019; 14: 1666-1671